Plant-derived cannabinoids as anticancer agents

Autor: O’Reilly, Eve M., Cosgrave, Joanne M., Gallagher, William M., Perry, Antoinette S.

Publikováno v: In Trends in Cancer May 2022 8(5):350-357

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells

Autor: O’Reilly, Eve, Khalifa, Karima, Cosgrave, Joanne, Azam, Haleema, Prencipe, Maria, Simpson, Jeremy C., Gallagher, William M., Perry, Antoinette S.

Publikováno v: Journal of Natural Products; September 2023, Vol. 86 Issue: 9 p2151-2161, 11p

Investigating chemopreventive and chemotherapeutic applications of cannabinoids in prostate cancer

Autor: O'Reilly, Eve

Prostate cancer is the 5th leading cause of cancer death in men, responsible for more than 375,000 deaths worldwide in 2020. For patients with localised prostate cancer, the 5-year survival rate is close to 100%. However, metastatic prostate cancer r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1061::07126dd1cce8c450e4be756fef13ab83

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

Autor: Zhao, Fang, Olkhov-Mitsel, Ekaterina, Kamdar, Shivani, Jeyapala, Renu, Garcia, Julia, Hurst, Rachel, Hanna, Marcelino Yazbek, Mills, Robert, Tuzova, Alexandra V., O’Reilly, Eve, Kelly, Sarah, Cooper, Colin, Brewer, Daniel, Perry, Antoinette S., Clark, Jeremy, Fleshner, Neil, Bapat, Bharati, Bristow, Rob, Parker, Chris, Mills, Ian, Pandha, Hardev, Whitaker, Hayley, Neal, David, Olivan, Mireia, Leung, Hing, Perry, Antoinette, Sanda, Martin, Schalken, Jack

Publikováno v: Clinical Epigenetics
Clinical Epigenetics, 10, 1, pp. 147
Clinical Epigenetics, Vol 10, Iss 1, Pp 1-12 (2018)
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical Epigenetics, 10, 147

Background Prevention of unnecessary biopsies and overtreatment of indolent disease remains a challenge in the management of prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk and high-risk) diseases

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7ea0b464b4f4297630aae05ff3d0f7
https://doi.org/10.1186/s13148-018-0575-z